Cervical Cancer and Hodgkin Lymphoma Linked to Higher ASCVD Risk: Study

The study, published in PLoS Medicine, analyzed long-term follow-up data from cancer survivors to evaluate subsequent cardiovascular outcomes. ASCVD encompasses coronary artery disease, myocardial infarction, and ischemic stroke, and remains a leading cause of morbidity and mortality worldwide. While cancer therapies have long been associated with cardiovascular toxicity, the study’s findings suggest that the elevated risk in cervical cancer and Hodgkin lymphoma patients may extend beyond treatment-related factors, potentially involving disease-specific inflammatory or immunologic mechanisms. Researchers reported that individuals with a history of cervical cancer experienced a statistically significant increase in ASCVD incidence compared to matched controls without cancer. Similarly, survivors of Hodgkin lymphoma exhibited higher rates of coronary and cerebrovascular events, even after adjusting for conventional cardiovascular risk factors such as age, smoking, diabetes, and hypertension. Other malignancies in the cohort did not show a comparable association, indicating that these two cancer types may uniquely influence vascular pathology. The authors emphasize that these findings should encourage clinicians to integrate cardiovascular risk assessment and monitoring into survivorship care plans for patients with cervical cancer and Hodgkin lymphoma. Early identification of high-risk individuals can facilitate preventive strategies, including lifestyle interventions, pharmacologic therapies, and tailored follow-up. Further research is needed to clarify the underlying mechanisms linking these cancers to ASCVD, including potential roles of chronic inflammation, radiation exposure, and immune dysregulation. Understanding these pathways may lead to targeted interventions that reduce cardiovascular risk without compromising oncologic outcomes. Reference: van Nimwegen, F.A., et al. (2007). Risk of atherosclerotic cardiovascular disease after treatment for cervical cancer and Hodgkin lymphoma: a prospective cohort study. PLoS Medicine, 4(12), e365. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290291/